Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02181621 · ClinicalTrials.gov registry record · NA
A RCT to Compare the Effects of Two Wound Products on Biofilm Disruption in DFUs
A NA study, sponsored by Smith & Nephew.
- Terminated
- Registry status
- NA
- Development phase
- 19
- Enrollment target
NCT02181621: Clinical Trial NA study, sponsored by Smith & Nephew.
NCT02181621 is a NA study that was terminated before completion, run by Smith & Nephew. The registered enrollment target is 19 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02181621, a NA study, was terminated before completion, sponsored by Smith & Nephew.
- TERMINATED
- Registry status
- NA
- Development phase
- 19 participants
- Enrollment target
Study Summary
This study is a prospective comparative study to determine if an Iodine Gel (Iodosorb◊) is better than standard dressing (Solosite◊ gel) in disruption of biofilm (small microorganism bacteria similar to plaque on teeth) on the wound bed diabetic foot ulcers. ◊ Trademark of Smith \& Nephew
Primary Outcome
The primary variable was the within-patient change from Baseline in log\^10 biofilm-protected bacteria count from Baseline (initial assessment) to Week 4, as measured by curettage.
Interventions
- DEVICE Iodosorb
- DEVICE Solosite gel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2014-08 |
| Est. Completion | 2015-10 |
| Phase | NA |
Why NCT02181621 stopped before completion
NCT02181621 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which Iodosorb is the first listed.
NCT02181621 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02181621 about?
NCT02181621 is a clinical study titled "A RCT to Compare the Effects of Two Wound Products on Biofilm Disruption in DFUs". This study is a prospective comparative study to determine if an Iodine Gel (Iodosorb◊) is better than standard dressing (Solosite◊ gel) in disruption of biofilm (small microorganism bacteria similar to plaque on teeth) on the wound bed diabetic foot ulcers. ◊ Trademark of Smith \& Nephew
What is the current status of trial NCT02181621?
This trial is currently terminated. It is a NA study. The enrollment target is 19 participants. The study started on 2014-08. Estimated completion is 2015-10.
What interventions are being tested in trial NCT02181621?
The interventions under investigation include: Iodosorb (DEVICE), Solosite gel (DEVICE).
Who is sponsoring clinical trial NCT02181621?
This trial is sponsored by Smith & Nephew, which has 72 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02181621's enrollment target sits among peer trials
19 1861st of 2000 higher than 138 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia